‘Global Clinical Nutrition Market Worth $52bn In 2021’ Says Visiongain Report

21 August 2018
Pharma

Visiongain’s new report Global Clinical Nutrition Market Forecast 2017-2027: Infant Nutrition, Enteral Nutrition, Parenteral Nutrition indicates that the global clinical nutrition market will see $52bn in spending in 2021.
The global clinical nutrition market is estimated at $41bn in 2016 and is expected to grow at a CAGR of 5.3% from 2017-2027. The infant nutrition segment held the largest market share, with $24.1 billion in value in 2016 and is expected to grow at a CAGR of 4.9% for the period 2017-2027
The lead analyst of the report said: “Growing number of aging population, increasing number of premature birth and high birth rate, rising number of malnourished patients receiving treatment, and growing incidence of lifestyle-associated diseases have led to higher adoption of clinical nutrition.
The clinical nutrition market in Asia-Pacific is the largest and fastest growing in the world and it is expected that this trend will continue throughout the forecast period, owing to the high prevalence and increasing incidence of chronic diseases, developing healthcare infrastructure, increasing awareness about clinical nutrition and rising income.
From 2017 to 2027, the Asia Pacific clinical nutrition market is expected to grow at a CAGR of 6.2%, owing to increasing demand from countries, such as India and China. The increasing geriatric population is also expected to propel the growth in this regional market”
The 144-page report contains 150 charts that add visual analysis in order to explain the developing trends within the Global Clinical Nutrition Market.

Visiongain provides revenue forecasts for the period 2017-2027 as well as qualitative analyses for the leading segments of this market: Infant Nutrition (Milk-based, Soy-based, Organic, Probiotic/Prebiotic and Others), Enteral Nutrition (Standard and Enteral Nutrition for Chronic Illnesses) and Parenteral Nutrition.
The 144-page report offers market forecasts for North America (the US and Rest of North America), Europe (Germany, France, the UK and Rest of Europe), Asia-Pacific (China, Japan, India and Rest of Asia-Pacific) and Rest of the World (Middle East and Rest of RoW). The forecasts for these regional and national markets are further segmented by the leading segments and sub segments of the clinical nutrition market.

This report also discusses the leading companies that hold the majority of market shares in the clinical nutrition market: Baxter International, Abbott Laboratories, B. Braun Melsungen AG, Nestle S.A., Groupe Danone, Mead Johnson, Fresenius Kabi, Hospira and Perrigo.

The report Global Clinical Nutrition Market Forecast 2017-2027: Infant Nutrition, Enteral Nutrition, Parenteral Nutrition report will be of value to anyone who wants to better understand the clinical nutrition market and its various segments. It will be useful for businesses who wish to better comprehend the part of the market they are already involved in, or those wishing to enter or expand into a different regional or technical part of the clinical nutrition industry.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business conferences, newsletters, management reports and e-zines focusing on the automotive, chemical, cyber, defence, energy, pharmaceutical, materials and telecoms sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Oncology remains the largest disease area in the pharmaceutical business. The oncology market is dominated by big pharma companies and high price labels” says Visiongain report

Although price is still the most important competitive advantage for a biosimilar company, current discount rates are not enough to automatically convince the key stakeholders of a biosimilar’s value.

10 September 2019

Read

“Anti-Infective Agents market set to grow to $141bn by 2024” says new Visiongain report

The global anti-infective agents market is one that is driven by innovation. This is vital for maintaining the rich pipeline of anti-infective agents seen in the market today.

09 September 2019

Read

“Global thyroid gland disorder treatment market is anticipated to grow at a lucrative CAGR of 3.6% and anticipated to reach USD 3.21 Billion by 2029”, says Visiongain report.

Thyroid disease is one of today’s most prevalent hormonal illnesses. Hyperthyroidism, hypothyroidism, and thyroid nodules are the most common thyroid gland disorders.

05 September 2019

Read

“Global somatostatin analogs market is anticipated to grow at a lucrative CAGR of 5.3% and anticipated to reach USD 4.78 Bn by 2029”, says Visiongain report.

Somatostatin was used to diagnose gastrointestinal tract tumors and acromegaly in the clinical environment.

05 September 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever